Previous studies have revealed potential in inhibiting the individual protein products of various YAP/TAZ signature genes in diverse cancer types,132, 133 an example of such is bemcentinib, an inhibitor of AXL whose expression is directly mediated by the Hippo transcriptional module, which has been combined with pembrolizumab in recent clinical trials in PM.134. The gene discussed is AXL; the disease is cancer.